Allele and Regeneron Resolve COVID-19 Treatment Patent Dispute in Settlement

Allele Biotechnology and Regeneron Pharmaceuticals have reached a settlement in a patent infringement lawsuit concerning the development of treatments and vaccines for COVID-19. The litigation, which was resolved in a New York federal court, accused Regeneron of infringing on Allele’s patent in this domain. More details on the settlement emerged after a recent court announcement, signaling an end to this aspect of patent disputes related to COVID-19 innovations.